Literature DB >> 34157083

Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer.

M Weniger1,2, T Hank1, M Qadan1, D Ciprani1, T Michelakos1, H Niess2, C Heiliger2, M Ilmer2, J G D'Haese2, C R Ferrone1, A L Warshaw1, K D Lillemoe1, J Werner2, A Liss1, C Fernández-Del Castillo1.   

Abstract

BACKGROUND: An increasing body of evidence suggests that microbiota may promote progression of pancreatic ductal adenocarcinoma (PDAC). It was hypothesized that gammaproteobacteria (such as Klebsiella pneumoniae) influence survival in PDAC, and that quinolone treatment may attenuate this effect.
METHODS: This was a retrospective study of patients from the Massachusetts General Hospital (USA) and Ludwig-Maximilians-University (Germany) who underwent preoperative treatment and pancreatoduodenectomy for locally advanced or borderline resectable PDAC between January 2007 and December 2017, and for whom a bile culture was available. Associations between tumour characteristics, survival data, antibiotic use and results of intraoperative bile cultures were investigated. Survival was analysed using Kaplan-Meier curves and Cox regression analysis.
RESULTS: Analysis of a total of 211 patients revealed that an increasing number of pathogen species found in intraoperative bile cultures was associated with a decrease in progression-free survival (PFS) (-1·9 (95 per cent c.i. -3·3 to -0·5) months per species; P = 0·009). Adjuvant treatment with gemcitabine improved PFS in patients who were negative for K. pneumoniae (26·2 versus 15·3 months; P = 0·039), but not in those who tested positive (19·5 versus 13·2 months; P = 0·137). Quinolone treatment was associated with improved median overall survival (OS) independent of K. pneumoniae status (48·8 versus 26·2 months; P = 0·006) and among those who tested positive for K. pneumoniae (median not reached versus 18·8 months; P = 0·028). Patients with quinolone-resistant K. pneumoniae had shorter PFS than those with quinolone-sensitive K. pneumoniae (9·1 versus 18·8 months; P = 0·001).
CONCLUSION: K. pneumoniae may promote chemoresistance to adjuvant gemcitabine, and quinolone treatment is associated with improved survival.
© The Author(s) 2020. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2021        PMID: 34157083     DOI: 10.1002/bjs.12003

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  10 in total

Review 1.  The Cancer Microbiome: Recent Highlights and Knowledge Gaps.

Authors:  Reece J Knippel; Julia L Drewes; Cynthia L Sears
Journal:  Cancer Discov       Date:  2021-08-16       Impact factor: 39.397

Review 2.  Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications.

Authors:  Suneetha Amara; Li V Yang; Venkataswarup Tiriveedhi; Mahvish Muzaffar
Journal:  Cells       Date:  2022-06-11       Impact factor: 7.666

Review 3.  Microbiome-Friend or Foe of Pancreatic Cancer?

Authors:  Jaroslaw Daniluk; Urszula Daniluk; Pawel Rogalski; Andrzej Dabrowski; Agnieszka Swidnicka-Siergiejko
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

Review 4.  The role of microbiome in pancreatic cancer.

Authors:  Jenny Jing Li; Mojun Zhu; Purna C Kashyap; Nicholas Chia; Nguyen H Tran; Robert R McWilliams; Tanios S Bekaii-Saab; Wen Wee Ma
Journal:  Cancer Metastasis Rev       Date:  2021-08-28       Impact factor: 9.264

5.  Isolation of pancreatic microbiota from cystic precursors of pancreatic cancer with intracellular growth and DNA damaging properties.

Authors:  Asif Halimi; Giorgio Gabarrini; Michał Jacek Sobkowiak; Zeeshan Ateeb; Haleh Davanian; Rogier Aäron Gaiser; Urban Arnelo; Roberto Valente; Alicia Y W Wong; Carlos Fernández Moro; Marco Del Chiaro; Volkan Özenci; Margaret Sällberg Chen
Journal:  Gut Microbes       Date:  2021 Jan-Dec

6.  Characterization of Gut Microbiota and Exploration of Potential Predictive Model for Hepatocellular Carcinoma Microvascular Invasion.

Authors:  Ningning Zhang; Zeyu Wang; Jiayu Lv; Shuwen Zhang; Yang Liu; Tian Liu; Wang Li; Lan Gong; Xiaodong Zhang; Emad M El-Omar; Wei Lu
Journal:  Front Med (Lausanne)       Date:  2022-03-17

Review 7.  Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations.

Authors:  Zhou Chen; Shaofeng Zhang; Shi Dong; Hao Xu; Wence Zhou
Journal:  Front Immunol       Date:  2022-03-03       Impact factor: 7.561

Review 8.  Impact of microbiota-immunity axis in pancreatic cancer management.

Authors:  Ilenia Bartolini; Giulia Nannini; Matteo Risaliti; Francesco Matarazzo; Luca Moraldi; Maria Novella Ringressi; Antonio Taddei; Amedeo Amedei
Journal:  World J Gastroenterol       Date:  2022-08-28       Impact factor: 5.374

Review 9.  Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies.

Authors:  Anthony Turpin; Cindy Neuzillet; Elise Colle; Nelson Dusetti; Rémy Nicolle; Jérôme Cros; Louis de Mestier; Jean-Baptiste Bachet; Pascal Hammel
Journal:  Ther Adv Med Oncol       Date:  2022-09-06       Impact factor: 5.485

Review 10.  [Surgery for periampullary pancreatic cancer].

Authors:  Thomas Hank; Ulla Klaiber; Klaus Sahora; Martin Schindl; Oliver Strobel
Journal:  Chirurg       Date:  2021-07-14       Impact factor: 0.955

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.